Cell therapy weekly: Yescarta® becomes the first CAR-T therapy approved in China
This week: the China National Medical Products Administration has approved Yescarta® as the first CAR-T therapy in the country, the
Insight into the Progress in CAR-T Cell Therapy and Combination with Other Therapies for Glioblastoma
Glioblastoma (GBM) is the most common malignant primary brain cancer in adults. It is always resistant to existing treatments, including
Three cases of late-onset post CAR-T therapy isolated CNS relapse in R/R large B-cell lymphoma
CD19-chimeric antigen receptor T-cell (CAR T-cell) therapy has improved the outcomes of relapsed/refractory large B cell lymphoma significantly. However, about
The improvement of CAR-T cells for glioblastoma
Glioblastoma (GBM) is one of the deadliest malignancies. At present, there is no effective treatment, which is a serious
New CAR-T Technology in Solid Tumors From China
Glioblastoma (GBM) is one of the deadliest malignancies. At present, there is no effective treatment, which is a serious
Penn researchers find a way through the labyrinth keeping CAR-T from solid tumors
Glioblastoma (GBM) is one of the deadliest malignancies. At present, there is no effective treatment, which is a
CAR-T breakthrough therapeutic drugs CNCT19
Glioblastoma (GBM) is one of the deadliest malignancies. At present, there is no effective treatment, which is a serious
Professor Zhang Yonghong: CAR-T cell therapy is fully attacked in hematological tumors and solid tum
Your Content Goes Here Glioblastoma (GBM) is one of the deadliest malignancies. At present, there is no effective
Chinese scientists make T cells to enhance anti-tumor ability
Glioblastoma (GBM) is one of the deadliest malignancies. At present, there is no effective treatment, which is a
Your Microbiome and Cancer: What to Know
Glioblastoma (GBM) is one of the deadliest malignancies. At present, there is no effective treatment, which is a